-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 PlvWl+AYeWW1lWLos+m21pwzASECQPNTcIzsZmzqo7HECd/Aev3PErSgHIopRE5z
 ltPRH78AGTLFAsp72J8F2Q==

<SEC-DOCUMENT>0000950123-10-053697.txt : 20100527
<SEC-HEADER>0000950123-10-053697.hdr.sgml : 20100527
<ACCEPTANCE-DATETIME>20100527161734
ACCESSION NUMBER:		0000950123-10-053697
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20100524
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100527
DATE AS OF CHANGE:		20100527

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		10862881

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c01841e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B> <!-- xbrl,dc -->

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): May 24, 2010</B> <!-- /xbrl,dc -->

<P style="font-size: 24pt" align="center"><B>GEOVAX LABS, INC.<BR>
</B><FONT
style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-52091</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>87-0455038</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>1900 Lake Park
Drive<BR>
Suite 380<BR>
Smyrna, Georgia <BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>30080</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(678) 384-7220</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt; text-indent: 4%" align="left">This Form 8-K and
other reports filed by GeoVax Labs, Inc. (the &#8220;Registrant&#8221;) from
time to time with the Securities and Exchange Commission (collectively the
&#8220;Filings&#8221;) contain forward looking statements and information that
are based upon beliefs of, and information currently available to, the
Registrant&#8217;s management as well as estimates and assumptions made by the
registrant&#8217;s management. When used in the Filings the words
&#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;,
&#8220;expect&#8221;, &#8220;future&#8221;, &#8220;intend&#8221;,
&#8220;plan&#8221; or the negative if these terms and similar expressions as
they relate to the Registrant or the Registrant&#8217;s management identify
forward looking statements. Such statements reflect the current view of the
Registrant with respect to future events and are subject to risks,
uncertainties, assumptions and other factors relating to the Registrant&#8217;s
industry, operations and results of operations and any businesses that may be
acquired by the Registrant. Should one or more of these risks or uncertainties
materialize, or should the underlying assumptions prove incorrect, actual
results may differ significantly from those anticipated, believed, estimated,
expected, intended or planned.


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="7%">&nbsp;</TD>
  <TD width="3%">&nbsp;</TD>
  <TD width="90%">&nbsp;</TD>
 </TR>

 <TR valign="bottom">
  <TD valign="top" align="left"><B>Item&nbsp;5.02</B></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR>
</TABLE>
</DIV>


<P style="font-size: 10pt; text-indent: 4%" align="left">On May&nbsp;24, 2010,
director Peter M. Tsolinas advised the board of directors that he will not
stand for re-election at the next annual stockholders meeting and will resign
his current director position after completion of the road show for the
Company&#8217;s contemplated stock and warrants offering. Mr.&nbsp;Tsolinas is
a member of the audit and compensation committees of the board of directors.

<P style="font-size: 10pt; text-indent: 4%" align="left">The reasons cited by
Mr.&nbsp;Tsolinas for his resignation included health concerns, disagreement
with a proposed listing of Company stock on the NYSE Amex Equities stock
exchange, disagreement with the Board over its having allowed past stock sales
under a Rule&nbsp;10b5-1 plan by one director, and earlier plans, now
abandoned, of two directors to sell stock in the contemplated offering. The
health concerns Mr.&nbsp;Tsolinas cited included his age, 74, and advice of his
physician.

<P style="font-size: 10pt; text-indent: 4%" align="left">The Company notes that
the prior inclusion of two directors in the offering only permitted them to
sell if and after the Company had sold $30&nbsp;million of units in the
offering, the same restriction that applies to Emory University&#8217;s ability
to sell in the offering.

<P style="font-size: 10pt; text-indent: 4%" align="left">The Company thanks
Mr.&nbsp;Tsolinas for his service on the board of directors, and recognizes his
valued contributions to GeoVax over many years, both as a significant investor
and as a member of the board. His wise counsel will be missed.

<P style="font-size: 10pt; text-indent: 4%" align="left">A copy of
Mr.&nbsp;Tsolinas&#8217; letter to the Company is attached as Exhibit&nbsp;17.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements
and Exhibits.</B>

<P style="font-size: 10pt" align="left">(d)&nbsp;Exhibits

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD style="border-bottom: #000000 1px solid" nowrap align="left"><B>Exhibit
No.</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" nowrap
align="left"><B>Description of Exhibit</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">Exhibit&nbsp;17 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Written communication regarding resignation as
a director.</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 4%" align="left">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report on Form 8-K to be signed on its behalf by the
undersigned hereunto duly authorized.

<P style="font-size: 10pt" align="left">Dated: May&nbsp;27, 2010

<P style="font-size: 10pt; text-indent: 48%" align="left">GEOVAX LABS, INC.
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="48%">&nbsp;</TD>
  <TD width="4%">&nbsp;</TD>
  <TD width="48%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->

<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">By: </TD>
  <TD valign="top" align="left" style="border-bottom: #000000 1px solid">/s/ Robert T. McNally</TD>
 </TR>

 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Robert T. McNally <BR>
President and Chief Executive Officer</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-17.1
<SEQUENCE>2
<FILENAME>c01841exv17w1.htm
<DESCRIPTION>EXHIBIT 17.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 17.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>Exhibit&nbsp;17.1</B>

<P style="font-size: 10pt" align="left">May&nbsp;27, 2010

<P style="font-size: 10pt" align="left">GeoVax Labs, Inc.:

<P style="font-size: 10pt" align="left">As I communicated at our Board meeting,
I have decided not to stand for re-election as a Director of GeoVax Labs, Inc.
at the Company&#8217;s next Annual Meeting of Stockholders. Furthermore,
effective upon the conclusion of GeoVax&#8217;s upcoming road show for its
$30&nbsp;million financing effort, I intend to tender my immediate resignation.

<P style="font-size: 10pt" align="left">My reasons for stepping down from the
GeoVax Board are as follows:

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">1.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>I am in total disagreement, and voted against, the recent decision by our
Board to seek a listing of the Company&#8217;s stock on the NYSE Amex stock
exchange instead of Nasdaq.</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">2.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>The proxy that our shareholders voted on stated that through our offering
that GeoVax would apply for listing on the <U>Nasdaq</U>, in order that GeoVax
would have a greater platform for institutions as well as other private
investors to view our great science.</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">3.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>In my opinion the aforementioned switch signals that we have given up on
the plan that we originally set out for. Some of the people are stating that if
Amex was our target the R/S could have been 1 for 25 instead of 1 for 50.</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">4.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>On more than one occasion, I have expressed my total disagreement,
disappointment and frustration with the actions taken by Dr.&nbsp;Robinson in
2009 with regard to her planned sale of stock under a Rule&nbsp;10b-5 Plan.
Although Dr.&nbsp;Robinson terminated the plan, it came only after I announced
that I would leave the board if she continued. Recently her continued desire to
sell stock in the Company&#8217;s offering, along with the other founders of
GeoVax (Don Hildebrand and Emory University), have, in my estimation, caused
great harm to the Company&#8217;s stock value, as well as shareholder
confidence.</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">5.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>Lastly my own personal physical challenges are also an integral part of
my decision to step away at this time. Recent advice from my doctor after my
last physical provided me with enough evidence that at age of 74, I should step
way from any stressful situations.</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">As you all know, I have articulated my
position on each of the above points in much greater detail in our Board
meetings, so I have elected to forego further exposition here. I have
personally supported this company with several million dollars since 2006 as
well as guiding other friends, before my selection to the board, to look at our
company&#8217;s potential as well as an opportunity to do their part in wiping
out this dreadful disease.

<P style="font-size: 10pt" align="left">Dr.&nbsp;Robinson is a great scientist
and is duly recognized universally for her work in this field. It&#8217;s time
that the company now work relentlessly with passion and urgency, towards
achieving early results on our preventative trials, especially now that the FDA has given us the right to proceed with our
therapeutic trials.

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left">In closing, let me further state that I
truly believe in GeoVax&#8217;s science and that the Company will ultimately
achieve success. I wish you all the best of luck.

<P style="font-size: 10pt" align="left">Respectfully submitted:

<P style="font-size: 10pt" align="left">/s/ Peter M. Tsolinas

<P style="font-size: 10pt" align="left">Peter M. Tsolinas

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">5
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
